Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Actinic cheilitis: a treatment review.
Shah AY, Doherty SD, Rosen T. Shah AY, et al. Int J Dermatol. 2010 Nov;49(11):1225-34. doi: 10.1111/j.1365-4632.2010.04580.x. Int J Dermatol. 2010. PMID: 20964646 Review.
Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation.
De B, Venkatesan AM, Msaouel P, Ghia AJ, Li J, Yeboa DN, Nguyen QN, Bishop AJ, Jonasch E, Shah AY, Campbell MT, Wang J, Zurita-Saavedra AJ, Karam JA, Wood CG, Matin SF, Tannir NM, Tang C. De B, et al. Among authors: shah ay. BJU Int. 2022 May;129(5):610-620. doi: 10.1111/bju.15541. Epub 2021 Jul 23. BJU Int. 2022. PMID: 34228889 Free PMC article.
Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma.
Labbate CV, Hensley PJ, Miest TS, Qiao W, Adibi M, Shah AY, Chery L, Papadopoulos J, Siefker-Radtke AO, Gao J, Guo CC, Czerniak BA, Navai N, Kamat AM, Dinney CP, Campbell MT, Matin SF. Labbate CV, et al. Among authors: shah ay. Urol Oncol. 2022 Oct;40(10):454.e17-454.e23. doi: 10.1016/j.urolonc.2022.06.014. Epub 2022 Aug 10. Urol Oncol. 2022. PMID: 35961847
Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience.
Alhalabi O, Hasanov E, Wilson NR, Araujo J, Wang J, Campbell MT, Goswami S, Shah AY, Gao J, Msaouel P, Tannir NM. Alhalabi O, et al. Among authors: shah ay. Int J Cancer. 2021 Jul 15;149(2):387-393. doi: 10.1002/ijc.33560. Epub 2021 Mar 24. Int J Cancer. 2021. PMID: 33739450 Free article.
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma.
Campbell MT, Matin SF, Tam AL, Sheth RA, Ahrar K, Tidwell RS, Rao P, Karam JA, Wood CG, Tannir NM, Jonasch E, Gao J, Zurita AJ, Shah AY, Jindal S, Duan F, Basu S, Chen H, Espejo AB, Allison JP, Yadav SS, Sharma P. Campbell MT, et al. Among authors: shah ay. Nat Commun. 2021 Nov 4;12(1):6375. doi: 10.1038/s41467-021-26415-4. Nat Commun. 2021. PMID: 34737281 Free PMC article. Clinical Trial.
Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors.
Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Chahoud J, et al. Among authors: shah ay. Urol Oncol. 2021 Feb;39(2):134.e9-134.e16. doi: 10.1016/j.urolonc.2020.10.019. Epub 2020 Nov 10. Urol Oncol. 2021. PMID: 33187886
Landscape of Immunotherapy in Genitourinary Malignancies.
Ravindranathan D, Alhalabi O, Rafei H, Shah AY, Bilen MA. Ravindranathan D, et al. Among authors: shah ay. Adv Exp Med Biol. 2021;1342:143-192. doi: 10.1007/978-3-030-79308-1_5. Adv Exp Med Biol. 2021. PMID: 34972965 Review.
Optimizing management of upper tract urothelial carcinoma.
Campbell MT, Shah AY, Matin SF, Siefker-Radtke AO. Campbell MT, et al. Among authors: shah ay. Urol Oncol. 2017 Jul;35(7):492-498. doi: 10.1016/j.urolonc.2017.05.009. Epub 2017 Jun 1. Urol Oncol. 2017. PMID: 28579283 Review.
85 results